You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Alovudine

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Alovudine?

Alovudine is an investigational drug.

There have been 6 clinical trials for Alovudine. The most recent clinical trial was a Phase 2 trial, which was initiated on February 2nd 2020.

The most common disease conditions in clinical trials are HIV Infections, Immunologic Deficiency Syndromes, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are Lederle Laboratories, National Cancer Institute (NCI), and City of Hope Medical Center.

There are six hundred and twenty-four US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for Alovudine
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementNational Cancer Institute (NCI)Phase 2
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementECOG-ACRIN Cancer Research GroupPhase 2
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and ChemotherapyNational Cancer Institute (NCI)Phase 2

See all Alovudine clinical trials

Clinical Trial Summary for Alovudine

Top disease conditions for Alovudine
Top clinical trial sponsors for Alovudine

See all Alovudine clinical trials

US Patents for Alovudine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alovudine   Start Trial Pharmaceutical antiretroviral composition Cipla Limited (Mumbai, IN)   Start Trial
Alovudine   Start Trial Methods of treating inflammation associated airway diseases and viral infections WASHINGTON STATE UNIVERSITY (Pullman, WA) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, TX)   Start Trial
Alovudine   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
Alovudine   Start Trial Use of gelsolin to treat infections The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alovudine

Drugname Country Document Number Estimated Expiration Related US Patent
Alovudine Australia 2013336491 1989-12-31   Start Trial
Alovudine Brazil 112015006558 1989-12-31   Start Trial
Alovudine Canada 2885763 1989-12-31   Start Trial
Alovudine China 104884063 1989-12-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.